The association between metabolic syndrome and presence of frailty: a systematic review and meta-analysis

Jiang, Xiaoman; Xu, Xinyi; Ding, Lei; Lu, Jinling; Zhu, Hanfei; Zhao, Kang; Zhu, Shuqin; Xu, Qin

doi:10.1007/s41999-022-00688-4

Cited by 16 publications

(13 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…demonstrated that T2DM patients had an increased prevalence of sarcopenia compared to controls (OR: 1.635, p = .002), while a bidirectional association between sarcopenia and T2DM was suggested 57 . Along with sarcopenia, two recent large meta‐analyses showed that MetS has been associated with elevated risk of frailty (pooled OR:1.73, and OR: 1.82, respectively) 58,59 . Regarding T2DM, Hanlon et al.…”

Section: Sarcopenia and Frailty In Non‐hepatic Diseasesmentioning

confidence: 99%

“…57 Along with sarcopenia, two recent large meta-analyses showed that MetS has been associated with elevated risk of frailty (pooled OR:1.73, and OR: 1.82, respectively). 58,59 Regarding T2DM, Hanlon et al conducted a large meta-analysis of 118 eligible studies with a total number of 1,375,373 patients with T2DM and they pinpointed that frailty was consistently correlated with mortality. 60…”

Section: Sarcopenia and Frailty In Non-hepatic Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

The association of testosterone with sarcopenia and frailty in chronic liver disease

Chrysavgis,

Adamantou,

Angelousi

et al. 2023

Eur J Clin Investigation

View full text Add to dashboard Cite

BackgroundTestosterone is an important anabolic hormone responsible for maintaining body composition and muscle mass and circulates mostly albumin‐bound, or sex hormone binding globulin (SHBG)‐bound or free in the plasma. Of these fractions, the latter is bioactive and exerts the androgenic effects on male population. Liver cirrhosis, the advanced stage of any chronic liver disease characterized by permanent distortions to the hepatic architecture, disrupts the hypothalamic‐pituitary‐gonadal axis, leading to diminished levels of free testosterone and hypogonadism.MethodsWe retrieved the PubMed database to provide a synopsis of testosterone's physiology and action and summarize the effect of sarcopenia in pre‐cirrhotic and cirrhotic patients. Moreover, we scoped to provide insight into the relationship of testosterone levels with sarcopenia, frailty and survival in cirrhotic and non‐cirrhotic population as well as to discuss the efficacy of exogenous testosterone supplementation on the anthropometric parameters and survival of those patients.ResultsLow testosterone levels have been associated with sarcopenia, reduced body lean mass, decreased bone mineral density and frailty, thus leading to increased morbidity and mortality especially among cirrhotic patients. Furthermore, exogenous testosterone administration significantly ameliorated body composition on patients with chronic hepatic disease, without significant adverse effects. However, the current literature does not suggest any significant effect on survival of those patients. Moreover, the long‐term safety of testosterone use remains an open question.ConclusionLow serum testosterone is strongly correlated with sarcopenia, frailty, higher rate of hepatic decompensation and mortality. Nonetheless, exogenous supplementation of testosterone did not ameliorate the liver‐related outcomes and complications.

show abstract

Section: Sarcopenia and Frailty In Non‐hepatic Diseasesmentioning

confidence: 99%

Section: Sarcopenia and Frailty In Non-hepatic Diseasesmentioning

confidence: 99%

The association of testosterone with sarcopenia and frailty in chronic liver disease

Chrysavgis,

Adamantou,

Angelousi

et al. 2023

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…17 This score did not include diabetes, hypertension, and dyslipidemia and was expected to be able to evaluate frailty independently of MetS. The participants' frailty risks were categorized as low (score <5), intermediate (score [5][6][7][8][9][10][11][12][13][14][15], or high (score >15).…”

Section: Outcome and Exposuresmentioning

confidence: 99%

“…Sarcopenic obesity contributes to the risk of frailty and disability in ADLs and IADLs 11 . Moreover, recent meta‐analyses have clarified that metabolic syndrome (MetS) is significantly associated with frailty 12,13 . MetS correlates with frailty among young and middle‐aged adults (20–65 years) but not older adults (>65 years) 14 .…”

Section: Introductionmentioning

confidence: 99%

Effect of overweight/obesity and metabolic syndrome on frailty in middle‐aged and older Japanese adults

Nishida,

Yamada,

Sasaki

et al. 2023

Obesity Science & Practice

View full text Add to dashboard Cite

BackgroundThe potential for developing frailty exists in middle‐aged and older adults. While obesity and metabolic syndrome (MetS) increase the risk of frailty in older adults, this relationship remains unclear in middle‐aged adults, who are prone to developing lifestyle‐related diseases.ObjectiveTo examine the effect of overweight/obesity and MetS on frailty development in middle‐aged and older Japanese adults using real‐world data.MethodsThis nationwide cohort study used exhaustive health insurance claims data of 3,958,708 Japanese people from 2015 to 2019 provided by the Japan Health Insurance Association. Participants aged ≥35 and <70 years who received health checkups in 2015 were included. Multivariate logistic regression was used to assess the effect of body mass index (BMI) and MetS or MetS components (i.e., diabetes, hypertension, and dyslipidemia) in 2015 on frailty risk assessed using the hospital frailty risk score in 2019. Additionally, a subgroup analysis was performed to examine the interaction effects of MetS components and 4‐year weight change (%) on frailty risk among participants who were overweight and obese (BMI ≥25 kg/m2).ResultsIn 2019, 7,204 (0.2%) and 253,671 (6.4%) participants were at high and intermediate frailty risks, respectively. Obesity and MetS were independently associated with intermediate/high frailty risk (odds ratio (OR) 1.36, p<0.05; OR 1.23, p<0.05, respectively) and high frailty risk (OR 1.80, p<0.05; OR 1.37, p<0.05, respectively) in all participants. Although all MetS components were frailty risk factors, these effects diminished with age in both sexes. Subgroup analysis of patients with diabetes revealed that 5% to 10% weight loss was associated with reduced frailty risk in both sexes.ConclusionsObesity, MetS, and MetS components were independent frailty risk factors in middle‐aged and older Japanese adults. Weight loss of up to 10% over 4 years prevented frailty in patients with diabetes who were overweight and obese.This article is protected by copyright. All rights reserved.

show abstract

“…The positive association between frailty and MetS has gained wide recognition through numerous epidemiological studies. Notably, a meta-analysis comprising 11 observational studies revealed a significant correlation between MetS and the occurrence of frailty (5). Furthermore, in a cohort study of 1,499 older adults free from diabetes at the outset, those with MetS were found to have a higher risk of developing frailty (6).…”

Section: Introductionmentioning

confidence: 99%

Frailty, Mental Disorders, and Metabolic Syndrome: A Genetic Association and Mediation Mendelian Randomization Study

Deng,

Wang,

Nie

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective:To examine the genetic associations of metabolic syndrome (MetS) with frailty and mental disorders [depression, schizophrenia (SCZ), and bipolar disorder (BIP)], along with causality between frailty and MetS and the mediating role of mental disorders.Methods:The summary-level datasets were obtained from recent genome-wide association studies. The genetic correlation was explored from the perspectives of global and local genetic correlation. Univariate Mendelian Randomization (UMR) was used to investigate the causal link between frailty and metabolic syndrome (MetS), followed by multivariate MR to address the confounding effects of body mass index (BMI) and physical activity (PA). Finally, two-step MR analyses were conducted to examine whether the causal relationship was mediated by mental disorders.Results:The global genetic correlation analyses presented MetS was positively associated with frailty and depression, but reversely related to SCZ. Similarly, MetS was locally correlated to frailty, depression, and SCZ in numerous genomic regions. The UMR demonstrated that fragile people have a higher likelihood of suffering from MetS (OR: 2.773, 95% CI: 1.455-5.286,p= 0.002), and reversely people with MetS tended to be more fragile (beta: 0.211, 95% CI: 0.180-0.241,p< 0.001). This bidirectional causal association still existed even after adjusting for BMI and PA. The mediation analyses implied this causality was mediated by depression, but not SCZ and BIP.Conclusion:Our research provided evidence of genetic correlations between MetS and frailty, depression, and SCZ. Additionally, we discovered a bidirectional causality between frailty and MetS, with depression playing a significant mediating role.

show abstract

The association between metabolic syndrome and presence of frailty: a systematic review and meta-analysis

Cited by 16 publications

References 49 publications

The association of testosterone with sarcopenia and frailty in chronic liver disease

The association of testosterone with sarcopenia and frailty in chronic liver disease

Effect of overweight/obesity and metabolic syndrome on frailty in middle‐aged and older Japanese adults

Frailty, Mental Disorders, and Metabolic Syndrome: A Genetic Association and Mediation Mendelian Randomization Study

Contact Info

Product

Resources

About